Your SlideShare is downloading. ×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Worldwide Narket for in Vitro Diagnostic (IVD) Tests, 7th Edition, the


Published on

Published in: Technology, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide


  • 1. Get more info on this report!Worldwide Market for In Vitro Diagnostic (IVD) Tests, 7th Edition, TheAugust 1, 2010In seven best-selling editions, Shara Rosen has provided a total view of every aspect ofthe market for in vitro diagnostic (IVD) testing in one complete volume. The report, TheWorldwide Market for In Vitro Diagnostic Tests, is a testament to the Kaloramamethodology. Real industry knowledge combined with an exhaustive review of themedical, business, and company literature. Market numbers for business planningmatched with a discovery of the trends that are impacting the industry. A realisticforecast five years into the future for companies already participating in or consideringentry into this growing industry. The idea behind Kaloramas unique report is that theentire market can be captured in one volume and business planners can use it as a keyreference. Published every two years, this volume includes coverage of the mostimportant aspects of all of the major segments of clinical lab testing, including: Point of Care (POC), (Professional and Self-Testing) Core Lab (General Chemistries, Workstations, Analyzers) Immunoassays (Blood Gases, Urinalysis, Critical Care) Molecular Assays (Infectious Disease, Blood Screening, Inherited Diseases, Oncology, Pharmacodiagnostics, Tissue Typing, Prenatal) Hematology Coagulation (Lab-Based, POC, Genetic Markers) Microbiology and Virology Blood Banking (Grouping, Immunoassay Screens, NAT Screens) Histology and Cytology (Pap, ISH, IHC, traditional non-pap, HPV)For each of these sections, Shara Rosen reviews the key products dominating themarket, the innovations that are occurring, and the trends that are impacting thesegments. Market sizes, forecasts and shares are provided, as well as a geographicbreakdown of the segments, where possible. Changes in technology development,regulatory and reimbursement issues, clinical care, and business environments arediscussed. Current market numbers are presented for 2009, with projections giventhrough 2014. Kalorama Information’s Report - ‘The Bible of the IVD Industry’
  • 2. Many of the top IVD companies use this product for business planning, which meansthat this volume can provide a uniform standard for in vitro diagnostic market numbers.These are the numbers that it is very likely competitive companies will be using in theirplanning.This 900+ page edition greatly expands coverage of the field and tracks the mostimportant developments. A Global ReportIVD is a worldwide business. While the US is a large healthcare market, much of thedynamism occurs in other areas. Many of the most interesting developments areoccurring in emerging markets. As part of its coverage, the report breaks down theentire IVD market for the following regions. North America Europe (EU) Eastern Europe South America Asia (China and India as subsegments) Rest of World A Report Designed for a Changing IndustryIn this seventh edition of The Worldwide Market for In Vitro Diagnostic Tests KaloramaInformation has reorganized the presentation of the IVD market in a manner that betterreflects how the industry has evolved. In the past, molecular testing was a small emerging discipline that related to chlamydia, gonorrhea, TB, and some inherited diseases. Now molecular technologies are impacting several areas of diagnostics. Molecular diagnostics has its own chapter but also is present in those other areas. Trends such as pharmacodiagnostics, molecular poc and test services are put in a context. The reports approach reflects the increasing use of automation in the lab; core lab section includes both workstation and automated panel revenues. The report‘s profiles distinguish between companies that are leaders in all aspects of IVD, those that lead in one particular area or a few, and those that are innovative but not yet large. We track ‘laggards’ - companies from the past few years that have failed due to financing or product failure. IVD Companies have been busy. The report examines the major mergers as well as partnerships, distribution agreements. A comparison and contrast of India and China - important emerging markets for IVD. But not always well-understood ones. There is discussion of the role of the new government focus on EMR and how it impacts IVD devices.
  • 3. Healthcare statistics for various countries -healthcare spending as a percent of GDP, new hospitals, cost increases and other information. Tables that document the innovative products being developed in each area of IVD. Country-level Breakout of IVD market for major European and Asian countries. The Impact of US Health Care Reform The Spread of Wireless Diagnostics and Remote Monitoring New Screening Guidelines and Market Impact Chronic vs. Infectious Disease Strange Bedfellows? Analysis fn the IVD Industry Consolidation The Continued Molecularization of Devices The Current Economic Situation: Recession: Post-Recession? The report looks at where non-Invasive Sampling PGx and SNP Testing IVD and the Promise of Personalized Medicine has been a discussion for years. Now it is closer to reality. The report provides an Update on the Regulation of Novel Devices Focus on the Continued Fight against Nosocomial Infections Innovations in Blood Banking Histology/Cytology innovations; the role of FISH testing and Digital ImagesTable of ContentsCHAPTER ONE: EXECUTIVE SUMMARY Introduction -Doing More with Less Scope and Methodology Size and Growth of the Market Regional Breakout - Major Countries Regional Breakout- Emerging Countries IVD Market Growth Indicators Lean Industry Group Purchasing Healthcare Reform Aging Population Emerging Markets Predicted Changes in the IVD Market Top Companies Market Trends Human Genome Project Remote Monitoring Development of IVD Product Choices Educated Consumers Reimbursement Need to Document Home Care Benefits
  • 4. CHAPTER TWO: INTRODUCTION New Report Design Note on Acquired Companies Lab Medicine Disciplines and Applications Definitions Market Analysis of IVD Market Segments The Big Get Bigger Licenses and Collaboration agreements Test Services Top Suppliers and Niche Players Laggards Point of View A Note on 6th Edition and 7th Edition VariancesCHAPTER THREE: OVERVIEW OF GLOBAL IN VITRO DIAGNOSTIC MARKETS Background Population and Disease Demographics, Worldwide Regional Segments of the World IVD Market and IVD Market Evolution Latin American IVD Sales, 2009 and 2014 ($ million) Special Topics Special Topics Initiatives to Support Healthcare Delivery, Worldwide China and India - Contrast and Compare India World Demand for IVD Tests and Services Insurance Costs, Worldwide An Overview of Medical Tourism Specific Country Information The United States US Healthcare Reform Japan Europe Denmark Poland China IndiaCHAPTER FOUR: TRENDS AND INNOVATION The Economics of Healthcare in Economic Stress IVD in Recessionary Time Hospital Market Outlook Health Care Reform EMR Update Patients Seek Test Results
  • 5. Status of EMR Conversion Wireless Connectivity and Healthcare Efficiencies IVD Wireless Applications Connectivity Imperative for POC devices RALS Wireless Apps Everywhere Consumer Reaction to Wireless Devices Lab-on-a chip The search for non-invasive tools Saliva Breath Optical Techniques Patch Technology Wearable Sensors/Textiles Reimbursement Challenges and Developments The Biomarker Revolution The In Vivo - In Vitro Diagnostic ServiceCHAPTER FIVE: POINT-OF-CARE TESTS Overview The Major POC Test Players DTC - The Myth of Consumerism Market Analysis Diabetes Testing - Blood Glucose Monitoring (BGM) Blood Glucose Self-Testing Continuous Self Testing Blood Glucose Testing by Professionals Diabetes Testing - Glycated Hemoglobin The Commercial Outlook for POC TestsCHAPTER SIX: THE CORE LAB Core Lab Overview Workstations Automation Overview of Chemistry Tests Market Analysis Lab-based Chemistries Critical Care Analysis Continuous Testing Urinalysis The Commercial Outlook for Chemistry TestsCHAPTER SEVEN: IMMUNOASSAYS Overview of Immunoassays
  • 6. Special Topics The Role of Immunoassays in Disease Management Market Analysis: Leading Suppliers and Growth Potential Immunoassay Test Segments — Mature, Maturing and Emerging Mature Assay Segment Thyroid Function Therapeutic drug tests Anemia Tox/DAU Allergy Maturing Immunoassays Proteins Growth Immunoassays Tumor Markers Cardiac Markers Autoimmune Sepsis Diabetes Miscellaneous Point-of-care OTC and Professional Use Patient Self-tests (OTC) Pregnancy Testing The Commercial Outlook for ImmunoassaysCHAPTER EIGHT: MOLECULAR ASSAYS Overview Special Topics The Promise of Personalized Medicine - The $1000 Genome Molecular Testing Innovation - Sequencing and Mass Spectroscopy Molecular Testing Innovation: Technology and Players Market Analysis Nucleic Acid Tests Prenatal Chromosome Analysis Tissue Typing The Commercial Outlook for Molecular TestsCHAPTER NINE: HEMATOLOGY Overview Decentralized Hematology Testing Market Analysis: Leading Suppliers The Commercial Outlook for Hematology TestsCHAPTER TEN: COAGULATION Overview of Coagulation and Immunohematology Tests
  • 7. The PGx Debate Market Analysis Lab-based Testing Genetic Markers of Hypercoagulopathies Decentralized Coagulation testing - Professional Use Decentralized Coagulation testing - OTC Platelet Testing Leading Suppliers The Commercial Market for Coagulation TestsCHAPTER ELEVEN: MICROBIOLOGY AND VIROLOGY Overview Special Topics Infectious Disease Diagnostics in 2009 Global Disease Surveillance Hospital Acquired Infections (HAIs) Emerging Organisms and the Globalization of Infectious Diseases Market Analysis Supplies Microbial Identification and Antimicrobial Sensitivity Tests Blood Culture Rapid Tests Immunoassays - Lab Based Immunoassays - Rapid TB HIV Molecular Tests Figure 8-4 The Commercial Outlook for Microbiology / Virology TestsCHAPTER TWELVE: BLOOD BANKING SERVICES Overview Blood Management - are all these transfusions good medicine? Automation to save time Artificial Blood Products - renewed interest Market Analysis Blood Banking Diagnostics Market, 2009 and 2014 Blood Grouping Immunoassays Nucleic Acid Testing (NAT) Continues to Grow The Commercial Outlook for Blood BankingCHAPTER THIRTEEN: HISTOLOGY AND CYTOLOGY Overview
  • 8. Special Topics The Growth of Histology/Cytology Test Services Market Analysis Histology/Cytology Traditional Stains Immunohistochemistry and In situ hybridization Pharmacodiagnostic Histology Digital Imaging Tissue Microarrays Circulating Tumor Cells Flow Cytometry The Commercial Outlook for Histology and Cytology TestsCHAPTER FOURTEEN: COMPANY PROFILES: THE TOP TIER Abbott Diagnostics Recent Revenue History Key Comment Immunoassays Core Lab Hematology Molecular Histology Molecular Diagnostics Infectious Diseases - Molecular Oncology Abbott Diabetes Care Blood Bank Point of Care Microbiology Information Technology ARKRAY (formerly Kyoto Daiichi) Recent Revenue History Key Comment Becton, Dickinson and Company (BD) Recent Revenue History ($ million, estimated) Key Comment Histology Flow Cytometry Molecular Microbiology BD Vacutainer Blood Collection Products (Preanalytical Systems) Beckman Coulter Inc Recent Revenue History ($ million, * estimated) Key Comment Hematology Core Lab Automation
  • 9. ImmunoassaysCoagulationFOBFlow CytometryImage CytometryMolecularResearch MarketsThe Olympus franchiseBlood BankAutomationbioMérieux IncRecent Revenue HistoryKey CommentMicrobiologyInformation TechnologyImmunoassaysMolecularBio-Rad Laboratories IncRecent Revenue History ($ million, * estimated)Key CommentMicrobiologyImmunoassaysPoint of CareQuality ControlMass SpectroscopyGen-Probe IncRecent Revenue History ($ million)Key CommentBlood BankOncologyHologic, IncRecent Revenue History ($ million, estimated)Key CommentHistologyHPVInstrumentation Laboratory (IL)Recent Revenue History ($ million, estimated)Key CommentCoagulationCritical CareInverness Medical InnovationsRecent Revenue History ($ million, * estimated)Key CommentPOCOrtho Clinical DiagnosticsRecent Revenue History ($ million)
  • 10. Key CommentBlood BankCore labRemote SensingImmunoassaysInfectious DiseasesQIAGEN N.VRecent Revenue History ($ million, * estimated)Key CommentHistologyInfectious diseasesOncologyRadiometer A/SRecent Revenue HistoryKey CommentImmunoassaysRoche DiagnosticsRecent Revenue HistoryKey CommentDiabetes CarePoint-of-CareCore LabHistologyImmunoassaysH1N1PCRInfectious DiseasesBlood BankPersonalized medicineResearchSiemens Healthcare DiagnosticsRecent Revenue History ($ million)Key CommentCritical CareMicrobiologyAllergyHematologyCoagulationImmunoassaysUrinalysisCore LabConnectivityIn VivoSysmex CorporationRecent Revenue History ($ million)Key Comment
  • 11. Automation Hematology Remote Diagnostics Oncology Blood Bank Molecular IT Thermo Fisher Scientific Inc Recent Revenue History Key CommentCHAPTER FIFTEEN: COMPANY PROFILES: THE SECOND TIER Affymetrix, Inc Recent Revenue History (product sales, $ million) Key Comment Agendia BV Recent Revenue History Key Comment Axis-Shield plc Recent Revenue History ($ million) Key Comment Bruker BioSciences Corporation Recent Revenue History Key Comment Celera Diagnostics Recent Revenue History ($ million)* Key Comment Infectious Diseases Cepheid Recent Revenue History ($ million) Key Comment Clarient Inc. (formerly ChromaVision) Recent Revenue History ($ million) Key Comment Clinical Data, Inc Recent Revenue History ($ million) Key Comment Cardiac Oncology Danaher Corporation Recent Revenue History Key Comment DiaSorin S.p.A Recent Revenue History ($ million) Key Comment Eiken Chemical Co., Ltd
  • 12. Recent Revenue History (not all clinical diagnostics) ($ million)Key CommentELITech GroupRecent Revenue History ($ million)Key CommentFujirebio Diagnostics, IncRecent Revenue History ($ million)Key CommentGenomic Health, IncRecent Revenue History ($ million)Key CommentGenzyme GeneticsRecent Revenue History ($ million)Key CommentInnogenetics NVRecent Revenue History ($ million)Key CommentInternational Technidyne Corp (ITC)Recent Revenue HistoryKey CommentIRIS International, IncRecent Revenue History ($ million)Key CommentUrinalysisMolecularLaboratory Corporation of America Holdings (LabCorp)Recent Revenue History ($ million)Key CommentLife TechnologiesKey CommentLuminex CorporationRecent Revenue History ($ million)Key CommentMagellan BiosciencesRecent Revenue HistoryKey CommentA. Menarini DiagnosticsRecent Revenue HistoryKey CommentMindray Bio-Medical Electronics Co., LtdRecent Revenue History ($ million, estimated)Key CommentMonogram Biosciences, Inc. (formerly ViroLogic)Recent Revenue History ($ million)Key CommentMyriad Genetics, Inc
  • 13. Recent Revenue History ($ million)Key CommentNanosphere, IncRecent Revenue HistoryKey CommentImmunoassaysNova BiomedicalRecent Revenue HistoryKey CommentPerkinElmer, IncRecent Revenue History ($ million)Key CommentPrenatal and Neonatal ScreeningPhadia ABRecent Revenue History ($ million)Key CommentAutoimmuneQuest DiagnosticsRecent Revenue History ($ million)Key CommentHIVOncologyPharmacodiagnosticsNeonatalQuidel CorporationRecent Revenue History ($ million)Key CommentRandox Laboratories LtdRecent Revenue HistoryKey CommentQuality ControlRosetta Genomics LtdRecent Revenue HistoryKey CommentSequenomRecent Revenue History ($ million)Key CommentThird Wave Technologies IncRecent Revenue History ($ million)Key CommentTOSOH CorporationRecent Revenue History ($ million, estimated)Key CommentTrinity Biotech plcRecent Revenue History ($ million, estimated)Key Comment
  • 14. Immunoassays HIV Coagulation Veridex, LLC Recent Revenue History Key Comment Werfen Group S.A Key CommentCHAPTER SIXTEEN: COMPANY PROFILES - THE THIRD TIER 3M Medical Diagnostics AcroMetrix Advanced Liquid Logic, Inc AltheaDx Technologies, Inc AMDL Diagnostics, Inc. (ADI) Arrayit Diagnostics Inc AviaraDx (formerly Arcturus Biosciences) Biocare Medical LLC Biotage AB (formerly Pyrosequencing Technologies) bioTheranostics BioTrove, Inc China Medical Technologies, Inc DxS Ltd Envision ALR Epigenomics AG Exosome Diagnostics Inc Grifols, S.A Idaho Technology Inc iKaryos Diagnostics Interleukin Genetics, Inc Intrinsic Bioprobes Inc Ionian Technologies, Inc Linkage Biosciences, Inc Millipore Corporation Nanogen Inc OncoMethylome Sciences S.A OPTI Medical Systems OptiGene Ltd Polymedco, Inc Saladax Biomedical, Inc. (SBI) SensiGen LLC Source MDx Spartan Bioscience Inc SQI Diagnostics Inc TessArae, LLC Transgenomic Inc
  • 15. TrimGen Corporation TrovaGene, Inc Vermillion Inc Wako Pure Chemical Industries, LtdCHAPTER SEVENTEEN: COMPANY PROFILES - BLOOD BANK SPECIALISTS AbSorber AB Arteriocyte, Inc Biotest AG CaridianBCT Inc. (formerly Gambro BCT) Cerus Corporation Daxor Corporation Fenwal Inc Immucor, Inc IntelliDOT Corp Novartis Vaccines and Diagnostics/Chiron Progenika Inc Quotient Biodiagnostics Inc Verax Biomedical IncCHAPTER EIGHTEEN: COMPANY PROFILES - COAGULATION SPECIALISTS Accumetrics Corgenix Medical Corporation Diagnostica StagoCHAPTER NINETEEN: COMPANY PROFILES - DIABETES SPECIALISTS AgaMetrix, Inc Bayer Diabetes Care Animas Corporation Bionime Corporation BodyTel Scientific, Inc DexCom, Inc Diabetech, LP Diagnostic Devices, Inc Entra Health Systems Fora Care Home Diagnostics, Inc Insulet Corporation Lifescan Inc Medtronic Inc OrSense Ltd Smiths Medical MD, Inc. (formerly Deltec, Inc.) Solianis Monitoring AG
  • 16. CHAPTER TWENTY COMPANY PROFILES - HEMATOLOGY SPECIALISTS Burnet Institute CellaVision AB Chempaq A/S Guava Technologies, Inc Horiba Medical Partec GmbH PointCare Technologies QBC Diagnostics, Inc Zyomyx IncCHAPTER TWENTY-ONE: COMPANY PROFILES - HISTOLOGY SPECIALISTS Aperio Technologies, Inc BioImagene Celerus Diagnostics Compucyte Corporation CytoCore, Inc Dako A/S Expression Pathology Inc Genetix Applied Imaging HistoRx, Inc Ikonisys, Inc InterGenetics Inc mtm laboratories AG Pathwork Diagnostics Vision BioSystems LtdCHAPTER TWENTY-TWO: COMPANY PROFILES - IMMUNOASSAY SPECIALISTS Adlyfe, Inc Akers Biosciences, Inc Amorfix Life Sciences Ltd Atherotech Avioq, Inc Axela Biosensors, Inc BG Medicine Inc Biomerica Inc BioPorto A/S BioSystems International (BSI) B·R·A·H·M·S Aktiengesellschaft CeMines, Inc Concateno Plc Cylex Incorporated Decision Biomarkers Inc Immunodiagnostic Systems Ltd Innotrac Diagnostics Oy
  • 17. Inova Diagnostics Inc IVAX Diagnostics, Inc LifeAssays AB Meridian Bioscience, Inc Miraculins Inc Ridge Diagnostics, Inc Shanghai Kehua Bio-engineering SpectraCell Laboratories, IncCHAPTER TWENTY-THREE: COMPANY PROFILES - MICROBIOLOGYSPECIALISTS 3QBD Accelr8 Technology Corporation Advanced Analytical Technologies Inc AdvanDx, Inc Arbor Vita Corporation bioLytical Laboratories BioVei Incorporated Cellestis Ltd Chembio Diagnostic Systems, Inc Copan Diagnostics Inc Diagnostic HYBRIDS, Inc. (DHI) Dynacon Inc eGenomics, Inc Enigma Diagnostics Limited Focus Diagnostics, Inc GlysBy Hain Lifescience GmbH Innovotech Inc Liofilchem s.r.l MicroPhage, Inc Mobidiag OyCHAPTER TWENTY-FOUR: COMPANY PROFILES - MOLECULAR TESTSPECIALISTS Arrayit Diagnostics Inc Advanced Analytical Technologies, Inc. (AATI) Arcxis Biotechnologies AutoGenomics, Inc BioHelix Corporation CyGene Laboratories Inc DioGenix, Inc DNage GeneNews Limited Ipsogen
  • 18. KREATECH Biotechnology B.V Med BioGene, Inc. (MBI) Microchip Biotechnologies, Inc. (MBI) OncoMethylome Sciences S.A Orchid Cellmark Orion Genomics Psynomics Incorporated Rubicon Genomics, Inc Seegene, Inc Tepnel Life Sciences TwistDx, Ltd WaferGen Biosystems, IncCHAPTER TWENTY-FIVE: COMPANY PROFILES - POINT-OF-CARE SPECIALISTS 77 Elektronika Kft A/C Diagnostics Acon Laboratories, Inc Acrongenomics Inc Amic AB BioIQ ContraVac, Inc HemoCue AB Identa Corporation Philips Electronics NV QuantRx Biomedical Corporation Screening Devices Canada, Inc Sphere Medical Ltd Soar BioDynamics, Ltd VeriChip Corporation Vital DiagnosticsLIST OF EXHIBITS LIST OF TABLESCHAPTER ONE: EXECUTIVE SUMMARY Table 1-1: Exchange Rate Fluctuations, 2006-2009 Table 1-2: Worldwide In Vitro Diagnostic Reagent Sales by Country/Region 2009-2014 (N. America, Western Eruope, Eastern Europe, ROW, India, L. America, Japan, China) Figure 1-1: Worldwide IVD Market, 2009 and 2014 ($million) Figure 1-2: Regional Breakout of World IVD Market, 2009 Figure 1-3: Regional Breakout of World IVD Market, 2014 Table 1-3: Top IVD CompaniesCHAPTER TWO: INTRODUCTION
  • 19. Table 2-1: Worldwide In Vitro Diagnostic Sales by Product Market (Clinical Chemistry, Immunoassays, Hematology, Microbiology, Microbiology Molecular, Radioimmunoassays, Coagulation, Histology/Cytology, Nucleic Acid Assays, Blood Grouping/Typing, Blood Bank Molecular, Flow Cytometry, POC) 2009- 2014 ($million) Figure 2-1: Breakout of IVD Market by Segment Figure 2-2: Consolidation in IVD as of 2009 Table 2-2: Selected Diagnostics Industry Acquisitions, 2008-2009 (Company, Location, Details) Table 2-2 (cont.): Selected Diagnostics Industry Acquisitions, 2008-2009 Table 2-3: Selected Diagnostics Industry Distribution Agreements, 2008-2009 Table 2-3 (cont.): Selected Diagnostics Industry Distribution Agreements, 2008- 2009 Table 2-4: Selected Diagnostics Industry Collaborations and Licensing Agreements, 2008-2009 (Company, Location, Action, Details) Table 2-5: Selected Test Services, sales 2008-2009 (Company, Location, Area, 2008 Revenues, 2009 Revenues, CAGR) Figure 2-3: Growth Rate of Testing Companies vs. Industry Table 2-6: Selected CLIA-certified labs established in 2008 & 2009 (Company, Location, Details) Table 2-7: Revenues of Selected IVD Companies 2007-2009 Figure 2-4 Top Tier IVD Companies, 2007 and 2009 Table 2-8: Selected IVD Market Laggards, 2008-2009CHAPTER THREE: OVERVIEW OF GLOBAL IN VITRO DIAGNOSTIC MARKETS Table 3-1: Selected Disease Statistics, Worldwide, 2008 Table 3-2: Worldwide In Vitro Diagnostics Sales by Country/Region 2009-2014, (N. America, EU 15/W. Europe, Japan, China, L. America, India, EU 14/ E.Europe, ROW) Figure 3-1: Chinese IVD Sales, 2009 and 2014 Figure 3-2: Indian IVD Sales, 2009 and 2014 Figure 3-3: Latin American IVD Sales, 2009 and 2014 Table 3-3: Infrastructure Data for Major Markets, 2005-2006 * (India, China , U.S.) Table 3-4: Percent Change in Industrial Productivity, December 2007 to December 2008 Table 3-5: OECD Country Healthcare Statistics for US, Germany, Sweden, Canada, Italy, Spain, Australia, Netherlands, UK and France Figure 3-4: Healthcare Costs as a Percent of GDP for US, Germany, Sweden, Canada, Italy, Spain, Australia, Netherlands, UK and France Table 3-6: IVD Expenditure per person, 2009 for US, Italy, France, Japan, Germany, Spain, UK, Russia, Brazil, China, India Table 3-7: Number of Hospitals and Hospitals with Labs: US & Canada, Europe, Asia, Latin America, Africa, Oceana Table 3-7: Medical Cost Increases in 18 Countries, Worldwide, 2006-2008
  • 20. Figure 3-5: North American IVD Market (US and Canada), 2009 and 2014 Table 3-8: U.S. Lab Service Market, 2009 (Type[Hospital/Independent/POL], Market Share, Revenue) Figure 3-6: Japanese IVD Market Table 3-9: European Union IVD Sales by Country (Germany, Italy, France, Spain, UK, Belgium, Netherlands, Portugal, Greece, Sweden, Austria, Denmark, Finland, Ireland, Eastern Europe, Other), 2008CHAPTER FOUR: TRENDS AND INNOVATION Table 4-1: Average Unemployment Rates, 2009 Table 4-2: Selected POC Wireless Innovations, 2008-2009 (Company, Location, Details, Status) Table 4-3: RALS connected POC systems, 2009 Table 4-4: Selected biochip and biosensor innovations, 2009 (Organization, Location, Target, Details) Table 4-5: Selected Innovations in Non-invasive Testing, 2008/09 Table 4-6: Selected Disease Markers in Exhaled Breath Table 4-7: Selected Novel Biomarkers Under InvestigationCHAPTER FIVE: POINT-OF-CARE TESTS Figure 5-1: POC Test Market , 2009 and 2014 ( ) Table 5-1: POC Sales by Test Category, worldwide 2009-2014 Figure 5-1: Breakout of POC Self Test Market (excluding Glucose) Table 5-2: POC Test Revenues of Selected IVD Companies, , estimated Table 5-3: World Glucose Monitoring Sales, by Company, 2007 - 2009 ( , estimated) Table 5-4: Selected Glucose Meter Innovations, 2008-2009 Table 5-5: Selected Data Management Enabled BGMs, 2009 Table 5-6: Selected Continuous BGM Sales, 2009 Table 5-7: Selected Continuous Blood Glucose Systems, 2009 Table 5-8: Selected POC HbA1c Devices, 2009CHAPTER SIX: THE CORE LAB Table 6-1: Clinical Chemistry/Immunoassay Sales, 2009-2014 (General Chemistries, Immunos on Workstations, Immunos on Immunoanalyzers) Figure 6-1: Immunoassay on Workstation Revenues Table 6-2: Core Lab Sales of the Top Five Manufacturers, 2007-2009, * Table 6-3: Lab Automation Summary, Number of Installations, Worldwide, 2009* (Pre Analytical, Track Connection) Table 6-4: Selected Core Lab Automation Innovations, 2008-2009 Table 6-5: Worldwide Clinical Chemistry Sales by Test Category 2009-2014 (General Chem, Blood Gases, Urinalysis, Critical Care POC) Table 6-6: Selected Critical Care Analysis Innovations, 2008-2009
  • 21. Table 6-8: Selected Urinalysis Innovations, 2008-2009CHAPTER SEVEN: IMMUNOASSAYS Table 7-1: Selected Immunoassays on Core Lab Instruments, 2008-2009 Table 7-2: Selected New Immunoassay Platforms, 2009 Table 7-3: Worldwide Lab-Based Immunoassay Sales by Analyte Type (Infectious Disease, Cardiac Marker, Tumor Marker, Autoimmune, Diabetes/HbA1c, Allergy, Thyroid, Proteins, Anemia, Therapetuic Drugs, Drugs of Abuse, Fertilty), 2009-2014 Figure 7-1 Selected Immunoassays on Core Lab Instruments, 2008-2009 Figure7-2: Immunoassay Sales by Type Table 7-4: Revenue History of Leading Immunoassay Vendors, 2007-2009 Table 7-5: Selected Tumor Marker Innovations, 2008-2009 Table 7-6: Selected Cardiac Marker Innovations, 2008-2009 Table 7-7: Selected Autoimmune Immunoassay Innovations, 2008-2009 Table 7-8: Selected Immunoassay Innovations, 2008-2009 Table 7-9: POC Immunoassay Test Sales by Test Category (Pregnancy/Ovulation, Drugs of Abuse, H. pylori, HIV, HbA1c, Cardiac Markers, Other) 2009-2014, Table 7-10: Selected Professional POC Test Innovations 2008-2009CHAPTER EIGHT: MOLECULAR ASSAYS Table 8-1: Selected Drug/Test Pharmacodiagnostic Combinatios Table 8-2 Selected Test Innovations Table 8-3: Selected Nucleic Acid Testing Platforms, 2008-2009 Table 8-4: Selected Pre-Analytical Sample Preparation Products, 2008-2009 Table 8-5: Selected Molecular QC Products, 2008-2009 Table 8-6: Worldwide Molecular Test Sales by Type, 2009-2014 (Infectious Disease, Blood Screening, Inherited Diseases, Oncology, Pharmacodiagnostics, Tissue Typing, Prenatal) Figure 8-1: Molecular Assay Sales, 2009 and 2014 Table 8-7: Molecular Test Revenues of Selected IVD Vendors, 2007-2009 Table 8-8: Worldwide Molecular Test Sales for Inherited Disease, Oncology and Pharmacodiagnostics, 2009-2014 Table 8-9: Selected Blood-based Molecular Tests Table 8-10: Selected Molecular Tests for Prenatal Analysis, 2008-2009 Table 8-11: Selected HLA Typing Tests, 2008-2009CHAPTER NINE: HEMATOLOGY Table 9-1: Selected Hematology Innovations, 2008-2009 Table 9-2: Selected POC Hematology Systems, 2008-2009 Figure 9-1: Hematoogy Diagnostics Market, 2009 and 2014 Table 9-3: Revenue History of the Major Hematology Vendors 2007-2009
  • 22. CHAPTER TEN: COAGULATION Table 10-1: Selected Warfarin Sensitivity Tests, 2009 Table 10-2: Worldwide Coagulation Sales by Segment ( ) 2009-2014 Table 10-3: Selected Coagulation Innovations, 2008-2009 Table 10-4: World POC Coagulation Sales, 2009 ( ) Table 10-5: Selected CLIA Waived PT Devices Table 10-6: Top Coagulation Company Revenues 2007 - 2009, estimated Table 10-7: Selected Coagulation Test Innovations, 2008-2009CHAPTER ELEVEN: MICROBIOLOGY AND VIROLOGY Table 11-1: Selected Advanced Microbiology Platforms Table 11-2: Worldwide Microbiology/Virology Sales by Type (Infectious Disease Immuno and Rapid, ID/AST, Molecular Infectious Disease Testing) 2009-2014, Table 11-3: Selected Chromogenic Growth Media Figure 11-1: ID/AST Systems Market, 2009 and 2014 Table 11-4: Revenue of Selected ID/AST Product Companies, 2009 (estimated) Table 11-5: Selected ID/AST Innovations, 2008-2009 Table 11-6: Lab-Based Infectious Disease Immunoassays, by Test, 2009 (Hepatitis, HIV, Sepsism Respiratory, STDs, TORCH, Parasitology, Mycology, Others) Table 11-7: Selected Infectious Disease Immunoassay Innovations, 2008-2009 Table 11-8: Selected Professional-use POC Tests for Infectious Diseases, 2008- 2009 Table 11-9: Molecular Test Sales, Infectious Diseases, 2009-2014, (HAI, HIV, Hepatitis, GC/Chlamydia, Respiratory, Organism ID, Mycobacteria/TB, others) Figure 11-3: Molecular Test Sales, Infectious Diseases by Disease Figure 11-4: Growth of Hospital Acquired Infections Diagnostics: Table 11-10: Selected Infectious Disease Molecular Test Innovations, 2008-2009CHAPTER TWELVE: BLOOD BANKING SERVICES Table 12-1: Blood Component Usage Table 12-2: Worldwide Blood Bank Sales, 2009-2014 Table 12-3: Selected Blood Screen Immunoassay Innovations, 2008-2009 Table 12-4 Selected Blood Bank InnovationsCHAPTER THIRTEEN: HISTOLOGY AND CYTOLOGY Table 13-1: Worldwide Histology/Cytology Sales by Type, 2009-2014 Table 13-2: Selected vendors of traditional histology stains Figure 13-1:Pap Smear Market Growth, 2009 and 2014 Table 13-3: Revenues of the Major Automated Histology Companies, 2007-2009 Table 13-4: Selected HPV test innovations, 2009 Figure 13-2: ISH Testing Market, 2009 and 2014
  • 23. Table 13-5: Selected Digital Imaging Innovations, 2008-2009 Table 13-6: Selected tissue microarray products, 2008-2009 Figure 13-3: Flow Cytometry Market, 2009 and 2014 Table 13-7: Revenue History of Flow Cytometry by Company, 2007-2009 Table 13-8: Selected CD4 Test Innovations, 2008-2009Available immediately for Online Download at 800.298.5699UK + +1.240.747.3093Fax: 240.747.3004